Showing 5191-5200 of 8785 results for "".
- Duobrii Lotion for Plaque Psoriasis Hits Shelveshttps://practicaldermatology.com/news/duobrii-lotion-for-plaque-psoriasis-hits-shelves/2460079/Ortho Dermatologics’ Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, is now available. Approved by the U.S. Food and Drug Administration on April 25, 2019, Duobrii is the first and only topical lotion that contains a uniq
- BioPharmX’s BPX-04 Performs Well in Rosacea Trialhttps://practicaldermatology.com/news/biopharmxs-bpx-04-performs-well-in-rosacea-trial/2460078/BioPharmX Corporation ‘s BPX-04, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea, performed well in a Phase 2b clinical trial, the Company reports. In the trial,
- New Data Support Clinical Utility of DermTech's PLAhttps://practicaldermatology.com/news/new-data-support-clinical-utility-of-dermtechs-pla/2460074/A new clinical study confirms the clinical utility of the DermTech’s pigmented lesion assay (PLA)in the early detection of melanoma. The PLA is a non-invasive test that uses molecular gene expression to identify malignant changes in a skin sample collected with adhesive
- Proactiv Works to Change the Conversation about Acne with New Initiativeshttps://practicaldermatology.com/news/proactiv-works-to-change-the-conversation-about-acne-with-new-initiatives/2460072/Proactiv is taking on the acne positivity movement with new initiatives aimed to help validate the emotional journey of people with acne and inspire compassion for others. As part of these initiatives, Brand Ambassador Kendall Jenner will continue
- Joanna Zucker is New CEO at PCA Skinhttps://practicaldermatology.com/news/joanna-zucker-is-new-ceo-at-pca-skin/2460071/With more than 25 years of experience in Consumer Packaged Goods and Retail, Joanna Zucker is assuming the role of Chief Executive Officer for PCA SKIN, part of Colgate-Palmolive's professional skin care portfolio. Ms. Zucker previously served in senior management and marketing
- Lilly: Taltz Tops Adalimumab for PsA in Head-to-Headhttps://practicaldermatology.com/news/lilly-taltz-tops-adalimumab-for-psa-in-head-to-head/2460069/Results of the phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA), presented as a late-breaking abstract at the European Congress of Rheumatology (EULAR) in Madrid, show that a significantly higher proportion of patients met the primary end
- Novartis: New Data Show Cosentyx Has Durable Response Across Psoriatic Diseasehttps://practicaldermatology.com/news/novartis-new-data-show-cosentyx-has-durable-response-across-psoriatic-disease/2460068/A new comprehensive analysis shows the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease, including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis. Data are derived from key Phase 3, random
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s en
- Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCDhttps://practicaldermatology.com/news/lilly-5-year-sustained-efficacy-and-safety-results-for-taltz-in-plaque-psoriasis-at-wcd/2460066/Patients with moderate- to severe plaque psoriasis who continued to receive Taltz® (ixekizumab) maintained high levels of skin clearance with no unexpected safety outcomes for up to five years of treatment, according to new data Eli Lilly and Company is presenting at the World Congress of Der
- Skin Metabolomics: Estee Lauder Presents New Research at WCDhttps://practicaldermatology.com/news/skin-metabolomics-estee-lauder-presents-new-research-at-wcd/2460063/The Estée Lauder Companies Inc.Research & Development (R&D) team will present data focused on new findings in skin metabolomics, skin defense, ingredient science, and anti-aging research at the 2019 World Congress of Dermatology (WCD) in Milan, Italy from June 10 -15.